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1218echocardiography may unveil myocardial dysfunction in the
otherwise nonhypertrophied segments seen on conventional 2-
dimensional echocardiography and CMR imaging. The major
limitation of this study is the small number of patients; thus, these
ﬁndings need to be further validated. Although we continue to try
to solve the Rubik’s Cube that is the left ventricle in normal and
diseased states (5), especially with regard to HCM, further insights
provided by myocardial mechanics in these patients could help
guide our moves.
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De-Novo Thrombus Formation
and Latent Ligation Failure
Following LAA Exclusion
Left atrial appendage (LAA) exclusion is becoming a popular
alternative for patients with atrial ﬁbrillation who are ineligible for
long-term anticoagulation. The LAA exclusion system (Lariat Su-
ture Delivery Device, SentreHEART Inc., Redwood City, Cali-
fornia) was evaluated in a non-randomized single-center study with
an immediate closure success rate (<1 mm of residual ﬂow) of 95%,
which was maintained up to 90 days as assessed by transesophageal
echocardiography (TEE). The recent data has demonstrated safety
and efﬁcacy up to 1 year following the procedure with the success
rate of up to 98% with no reported late device-associated thrombi
(1,2). We report 3 cases of importance with respect to management
of antiplatelet and anticoagulation therapy.
Patient #1. The ﬁrst patient is a 63-year-old man with paroxysmal
atrial ﬁbrillation and prior splenic infarct who was ineligible for
long-term anticoagulation because of underlying coagulopathy sec-
ondary to cryptogenic cirrhosis with a history of esophageal variceal
bleed. Intraoperative TEE conﬁrmed closure of the LAA with noevidence of residual leak immediately following the Lariat procedure
(Fig. 1A). The patient received no post-operative antiplatelet or
anticoagulant therapy. Routine follow-up TEE 3 months later
showed that the LAA remained obliterated; however, there was a
new mobile thrombus in the LAA remnant attached to the atrial
wall (Fig. 1B). Despite his bleeding risk, the patient was started
on warfarin and remained asymptomatic with no neurologic
sequelae. Repeat TEE 2 months later showed complete resolution
of thrombus.
Patient #2. The second patient is a 75-year-old woman with
persistent atrial ﬁbrillation and history of ischemic stroke who
had extreme difﬁculty in maintaining a therapeutic international
normalized ratio on warfarin. During the LAA exclusion proce-
dure, it was difﬁcult to obtain complete ostial closure of the LAA.
Intraoperative imaging with angiography and TEE showed a
small pouch remnant, but suggested most of the distal trabecu-
lated appendage was closed (Fig. 1C). This patient also received
no post-operative antiplatelet or anticoagulant therapy. Routine
follow-up by TEE 3 months later revealed a thrombus in the
LAA, which no longer appeared to be closed, suggesting latent
ligation failure (Fig. 1D).
Patient #3. Finally, a 76-year-old man also with persistent
atrial ﬁbrillation was referred for the LAA exclusion procedure
because of a history of intracerebral hemorrhage in addition to
gastrointestinal bleed while on warfarin. Intraoperative TEE and
angiography conﬁrmed complete closure of the LAA with no re-
sidual leak (Fig. 1E). At discharge, the patient was maintained on
aspirin and clopidogrel only. Follow-up TEE 3 months later
demonstrated thrombus formation in the LAA, which was no
longer ligated (Fig. 1F). Because of the presence of thrombus,
aspirin and clopidogrel were discontinued, and the patient was
started on warfarin.
Initially, the role of post-procedure antithrombotic therapy was
largely unknown, although it was suggested the Lariat device
would allow freedom from warfarin, especially immediately
following the procedure. This is a contradistinction to another
LAA closure device (Watchman, Boston Scientiﬁc, Natick,
Massachusetts), which requires warfarin post-operatively for at
least 45 days while the device endothelializes (3). Initially, the role
of anticoagulation immediately following the Lariat procedure was
unclear and a nonsystematic approach was applied. Recent data
showing long-term results for thromboembolic event reduction are
confounded by the high proportion of patients (61%) on warfarin
at the time of last follow-up (approximately 1 year). Because this
data can not conﬁrm freedom from thrombus formation without
anticoagulation, recent recommendations by Bartus et al. (2) now
suggest that patients with a CHADS2 (congestive heart failure;
hypertension >140/90 mm Hg, or on hypertension medication;
age $75 years; diabetes mellitus; and prior stroke, transient
ischemic attack, or thromboembolism) score of 2 or higher
who can tolerate anticoagulation continue warfarin.
As noted in this report, we present a case series of 3 patients
who at 3-month follow-up TEE, had evidence of de novo
thrombus formation: 1 adjacent to the ligated LAA; and 2 within
the LAA that no longer appeared to be ligated. One patient
received antiplatelet therapy; however, none were initiated on
anticoagulant therapy immediately after the procedure. Based on
Figure 1. Patient TEE Images
Immediate post-operative and 3-month follow-up transesophageal echocardiography (TEE) images from the 3 patients. Patient 1 immediately following the Lariat
procedure showing no residual leak (A), with follow-up TEE showing thrombus in the ligated appendage (B). Patient 2 showing less than 1 mm residual ﬂow
immediately after the procedure (C), with follow-up TEE showing ligation failure with thrombus (D). Patient 3 immediately post-procedure showing no residual ﬂow
(E), with follow-up TEE showing ligation failure and thrombus formation (F).
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1219our ﬁndings, we agree that antiplatelet or anticoagulant therapy
is advisable following the LAA exclusion procedure until routine
follow-up TEE can be performed to conﬁrm LAA closure and
absence of thrombus. Our center is now using short-term anti-
coagulation immediately following the Lariat procedure, unless
absolutely contraindicated, until follow-up TEE conﬁrms the
LAA remains ligated and free of thrombus. The ideal length of
anticoagulation treatment is unknown. Additionally, as evidenced
by our ﬁrst patient, thrombus formation was discovered adjacent
to a successfully ligated LAA, suggesting latent thrombosis is still
possible in patients who have short- and intermediate-term
closure success.
Ongoing, randomized clinical trials will be needed not only
to provide short- and long-term evidence that LAA exclusion
would prevent thromboembolic events, but these trials also
need to develop a protocol for discontinuing anticoagulation at
a pre-speciﬁed time point to assess the risk of intra-atrial thrombus
formation.James Gray, MD,* David Rubenson, MD
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